[Federal Register Volume 72, Number 215 (Wednesday, November 7, 2007)]
[Notices]
[Page 62873]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-21849]



[[Page 62873]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 9, 2007, Noramco 
Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-Oxide (9053).....................  I
Morphine-N-Oxide (9307)....................  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Opium, raw (9600)..........................  II
Opium poppy (9650).........................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the Schedule I 
controlled substances for internal testing; the Schedule II controlled 
substances will be manufactured in bulk for distribution to its 
customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administrator, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than January 7, 2008.

    Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-21849 Filed 11-6-07; 8:45 am]
BILLING CODE 4410-09-P